ADVERSE REACTIONS
In 718 patients treated for shorter periods, i.e., 2 weeks or less, with Cataflam® (diclofenac potassium immediate-release tablets), adverse reactions were reported one-half to one-tenth as frequently as by patients treated for longer periods. In a 6-month, double-blind trial comparing Cataflam (N=196) versus Voltaren® (diclofenac sodium delayed-release tablets) (N=197) versus ibuprofen (N=197), adverse reactions were similar in nature and frequency.
In patients taking Cataflam or other NSAIDs, the most frequently reported adverse experiences occurring in approximately 1%-10% of patients are:
Gastrointestinal experiences including: abdominal pain, constipation, diarrhea, dyspepsia, flatulence, gross bleeding/perforation, heartburn, nausea, GI ulcers (gastric/duodenal) and vomiting.
Abnormal renal function, anemia, dizziness, edema, elevated liver enzymes, headaches, increased bleeding time, pruritus, rashes and tinnitus.
Additional adverse experiences reported occasionally include:
Body as a Whole: fever, infection, sepsis
Cardiovascular System: congestive heart failure, hypertension, tachycardia, syncope
Digestive System: dry mouth, esophagitis, gastric/peptic ulcers, gastritis, gastrointestinal bleeding, glossitis, hematemesis, hepatitis, jaundice
Hemic and Lymphatic System: ecchymosis, eosinophilia, leukopenia, melena, purpura, rectal bleeding, stomatitis, thrombocytopenia
Metabolic and Nutritional: weight changes
Nervous System: anxiety, asthenia, confusion, depression, dream abnormalities, drowsiness, insomnia, malaise, nervousness, paresthesia, somnolence, tremors, vertigo
Respiratory System: asthma, dyspnea
Skin and Appendages: alopecia, photosensitivity, sweating increased
Special Senses: blurred vision
Urogenital System: cystitis, dysuria, hematuria, interstitial nephritis, oliguria/polyuria, proteinuria, renal failure
Other adverse reactions, which occur rarely are:
Body as a Whole: anaphylactic reactions, appetite changes, death
Cardiovascular System: arrhythmia, hypotension, myocardial infarction, palpitations, vasculitis
Digestive System: colitis, eructation, fulminant hepatitis with and without jaundice, liver failure, liver necrosis, pancreatitis
Hemic and Lymphatic System: agranulocytosis, hemolytic anemia, aplastic anemia, lymphadenopathy, pancytopenia
Metabolic and Nutritional: hyperglycemia
Nervous System: convulsions, coma, hallucinations, meningitis
Respiratory System: respiratory depression, pneumonia
Skin and Appendages: angioedema, toxic epidermal necrolysis, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, urticaria
Special Senses: conjunctivitis, hearing impairment
|
REPORTS OF SUSPECTED CATAFLAM SIDE EFFECTS / ADVERSE REACTIONS
Below is a sample of reports where side effects / adverse reactions may be related to Cataflam. The information is not vetted and should not be considered as verified clinical evidence.
Possible Cataflam side effects / adverse reactions in 3 month old female
Reported by a pharmacist from Costa Rica on 2011-10-19
Patient: 3 month old female
Reactions: Death, Skin Discolouration
Adverse event resulted in: death, hospitalization
Suspect drug(s):
Cataflam
Possible Cataflam side effects / adverse reactions in 83 year old female
Reported by a health professional (non-physician/pharmacist) from Hungary on 2011-10-20
Patient: 83 year old female
Reactions: Haemorrhage, Pain in Extremity, Oedema Peripheral, International Normalised Ratio Increased, Drug Interaction
Suspect drug(s):
Cataflam
Other drugs received by patient possibly interacting with the suspect drug: Atorvastatin
Dosage: unk
Simvastatin
Sintrom
Other drugs received by patient: Perindopril Erbumine; Indapamide; Metformin HCL; Allopurinol
Possible Cataflam side effects / adverse reactions in 24 year old female
Reported by a consumer/non-health professional from Brazil on 2011-10-31
Patient: 24 year old female
Reactions: Anxiety, Migraine, Vomiting, Dehydration
Suspect drug(s):
Cataflam
Dosage: unk ukn, unk
Administration route: Oral
Indication: Migraine
Diclofenac Sodium
Dosage: 50 mg, unk
Indication: Migraine
Other drugs received by patient: Naratriptan; Omeprazole
|